Next Generation Sequencing (NGS) is not a new technology. However, its application in biosafety testing and characterization is more recent. With NGS gaining regulatory acceptance for various testing applications within the biologics space, now is the perfect time to incorporate NGS into your testing programs. This webinar explores how NGS is being used in a cross-functional manner for required regulatory testing and will focus on applications such as: Identity with variant detection, adventitious virus detection, on/off target analysis for gene editors, genetic stability, and AAV characterization. Join us to learn more about this technology and its applications from leaders in the field.
In this webinar, you will learn:
- How cutting-edge NGS technology can be applied to biosafety and characterization testing to fulfil regulatory requirements.
- Where NGS fits into your process and how to leverage an expert testing partner.
- How including NGS in your testing portfolio can support corporate 3R sustainability goals for transitioning from in vivo testing.
Speaker
Bradley Hasson
Merck
Director of Lab Operations for NGS Services
Bradley Hasson is the director of lab operations for next-generation sequencing services. Brad leads a team of scientists, laboratory technicians, and bioinformaticians that perform NGS-based biosafety testing services in support of product characterization and release worldwide.
Brad has 15 years of experience developing and implementing molecular-based methods for the purposes of lot release and characterization testing in a variety of biologically derived products.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
Dauer:1h
Sprache:English
Sitzung 1:vorgestellt October 17, 2024
Um weiterzulesen, melden Sie sich bitte an oder erstellen ein Konto.
Sie haben kein Konto?